Send your comments and tips to whitecoat@globe.com
  Awards Beth Israel Deaconess Medical Ctr. Boston Medical Center Boston University Brigham and Women's Hospital Broad Institute Cambridge Health Alliance Caritas St. Elizabeth's Medical Ctr. Children's Hospital Boston Dana-Farber Cancer Institute Grants Harvard University Joslin Diabetes Center Lahey Clinic Mass. General Hospital Mass. Health Law McLean Hospital MIT New England Baptist Hospital Personnel Moves Public Health Research Short White Coat Tufts-New England Medical Center Tufts University UMass Memorial Medical Center University of Massachusetts VA Medical Centers    A Healthy Blog Running A Hospital Nature Network Boston SciBos - Corie Lok's blog Kevin, M.D. Blog, MD Nurse at small Dr. Gwenn Is In Healthy Children blog WBUR's CommonHealth Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram &
Gazette.
Boston Globe Health and Science staff:
Scott Allen Alice Dembner Carey Goldberg Liz Kowalczyk Stephen Smith Colin Nickerson Beth Daley Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor. Short White Coat blogger Ishani Ganguli Short White Coat blogger Jennifer Srygley  Week of:
November 11
Week of:
November 4
Week of:
October 28
Week of:
October 21
Week of:
October 14
Week of:
October 7
|
« In case you missed it: lessons from heart disease | Main | MGH group to study genes and heart attacks » Monday, April 9, 2007Today's Globe: anti-anemia drug roadblocks, AIDS orphans, bed sores, new hepatitis drugA licensing deal between Beth Israel Deaconess Medical Center and a Florida biotechnology company to produce a "super" form of an anti-anemia drug is in danger of foundering just two years after it was signed. As the creator of the first global center dedicated exclusively to health and human rights, at the Harvard School of Public Health, Countess Albina du Boisrouvray probably has as much hands-on experience in both as anyone. She's adopted the world's AIDS orphans as her cause. Until recently, most experts believed that bed sores were an unambiguous indicator of bad care. Also in Health/Science, the power of trash, Scrabble as a science and drug combinations. In Business & Innovation, for Vertex Pharmaceuticals Inc., the future hinges on a potential billion-dollar drug for hepatitis C and a liver-research conference about to kick off 3,700 miles away in Spain where it will unveil new data from human trials of the pill. Posted by Elizabeth Cooney at 06:25 AM
|
